Cytosorbents (NASDAQ:CTSO) Now Covered by Analysts at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Cytosorbents (NASDAQ:CTSO) in a report released on Tuesday. The firm set a “hold” rating on the medical research company’s stock.

Separately, D. Boral Capital reaffirmed a “buy” rating and set a $10.00 target price on shares of Cytosorbents in a report on Tuesday, February 25th. Two research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Cytosorbents presently has an average rating of “Moderate Buy” and an average target price of $4.67.

Cytosorbents Price Performance

Shares of NASDAQ:CTSO opened at $1.13 on Tuesday. The company has a market capitalization of $61.79 million, a PE ratio of -3.14 and a beta of 0.78. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.58 and a current ratio of 1.97. The stock has a fifty day moving average of $1.06 and a 200-day moving average of $1.05. Cytosorbents has a one year low of $0.70 and a one year high of $1.61.

Hedge Funds Weigh In On Cytosorbents

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Renaissance Technologies LLC boosted its position in shares of Cytosorbents by 10.6% in the fourth quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company’s stock worth $80,000 after buying an additional 8,400 shares during the period. Northern Trust Corp raised its position in Cytosorbents by 22.3% during the fourth quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock valued at $83,000 after buying an additional 16,701 shares during the period. Skylands Capital LLC lifted its stake in Cytosorbents by 1.0% in the 4th quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company’s stock worth $2,531,000 after acquiring an additional 26,195 shares in the last quarter. Geode Capital Management LLC boosted its position in Cytosorbents by 7.5% during the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after acquiring an additional 32,415 shares during the period. Finally, Millennium Management LLC purchased a new position in Cytosorbents during the 4th quarter valued at about $30,000. 32.87% of the stock is currently owned by hedge funds and other institutional investors.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.